Nanolayered siRNA Dressing for Sustained Localized Knockdown

The success of RNA interference (RNAi) in medicine relies on the development of technology capable of successfully delivering it to tissues of interest. Significant research has focused on the difficult task of systemic delivery of RNAi; however its local delivery could be a more easily realized app...

Full description

Bibliographic Details
Main Authors: Wang, Mary (Contributor), Hammond, Paula T (Author), Castleberry, Steven A (Author)
Other Authors: Harvard University- (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Castleberry, Steven A. (Contributor), Hammond, Paula T. (Contributor)
Format: Article
Language:English
Published: American Chemical Society (ACS), 2014-11-17T19:39:48Z.
Subjects:
Online Access:Get fulltext
Description
Summary:The success of RNA interference (RNAi) in medicine relies on the development of technology capable of successfully delivering it to tissues of interest. Significant research has focused on the difficult task of systemic delivery of RNAi; however its local delivery could be a more easily realized approach. Localized delivery is of particular interest for many medical applications, including the treatment of localized diseases, the modulation of cellular response to implants or tissue engineering constructs, and the management of wound healing and regenerative medicine. In this work we present an ultrathin electrostatically assembled coating for localized and sustained delivery of short interfering RNA (siRNA). This film was applied to a commercially available woven nylon dressing commonly used for surgical applications and was demonstrated to sustain significant knockdown of protein expression in multiple cell types for more than one week in vitro. Significantly, this coating can be easily applied to a medically relevant device and requires no externally delivered transfection agents for effective delivery of siRNA. These results present promising opportunities for the localized administration of RNAi.
Massachusetts Institute of Technology. Institute for Soldier Nanotechnologies (Contract W911NF-07-D0004)
Sanofi Aventis (Firm)
Massachusetts Institute of Technology. Center for Biomedical Innovation